HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $87 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Legend Biotech (NASDAQ:LEGN) and maintained an $87 price target.

March 13, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. reaffirms a Buy rating on Legend Biotech with an $87 price target.
The reiteration of a Buy rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100